FDA

Biotech Adam Feuerstein

STAT Plus: Gilead wins U.S. approval for drug to treat autoimmune liver disease

D.C. Diagnosis Sarah Owermohle

The politics of mifepristone in the 2024 election

Politics Nicholas Florko

STAT Plus: Meet the billionaire media mogul who’s taking on the food industry

First Opinion Suzanne Robotti

The FDA should withdraw approval of more than 400 tainted medicines

First Opinion Susannah Baruch

Getting to ‘Plan B’ for psychedelic medicine: Lessons from reproductive health

Health Olivia Goldhill and Meghana Keshavan

STAT Plus: FDA rejects MDMA as a psychedelic treatment for PTSD

Pharma Isabella Cueto

STAT Plus: FDA approves EpiPen alternative, a nasal spray for anaphylaxis

Health Meghana Keshavan and Olivia Goldhill

MDMA therapy is facing an imminent FDA decision. Here’s what you need to know

Health tech Lizzy Lawrence

STAT Plus: AI app claiming to diagnose STIs from penis pictures shut down after FTC scrutiny

Health Lev Facher

FDA approves Purdue Pharma’s controversial new overdose-reversal medication

Health tech Lizzy Lawrence

STAT Plus: Medicare finalizes reimbursement rule for breakthrough medical devices

Health tech Mohana Ravindranath

STAT Plus: FDA’s digital health advisory committee takes shape, and a critique of cost-effectiveness studies

First Opinion Darrell Rigel

Rising rates of skin cancer: The cost of FDA’s inaction on novel sunscreen products

Politics Sarah Owermohle and Rachel Cohrs Zhang

STAT Plus: 7 key people who could shape Trump’s health care policy

The Readout LOUD Elaine Chen, Adam Feuerstein, and Allison DeAngelis

STAT Plus: UnitedHealth’s doctor empire, an FDA departure, and Viking’s obesity moves

First Opinion Thomas R. Insel

Adding psychotherapy to drug therapy works, but the FDA may not be able to handle it

Exclusive Lizzy Lawrence

STAT Plus: Jeff Shuren, medical devices head at FDA, to leave the agency

First Opinion Richard Macary

Fixing the reimbursement and coverage divide between ‘breakthrough’ drugs and medical devices

Politics Olivia Goldhill

STAT Plus: FDA investigators have not spoken with patients and others alleging misconduct in MDMA trials

Politics Nicholas Florko

STAT Plus: ‘Legal’ psychedelic mushrooms actually contain illegal hallucinogens, study shows

Exclusive Nicholas Florko

STAT Plus: Applesauce lead contamination could not have been prevented, top FDA official suggests

The Readout Elaine Chen

STAT Plus: Roche looks to have a competitive GLP-1 drug

The Readout Meghana Keshavan

STAT Plus: What are the odds we get an heir to Paxlovid?

Exclusive Nicholas Florko

STAT Plus: Top FDA officials weighing regulation of ultra-processed foods, internal documents show

The Readout Meghana Keshavan

STAT Plus: Element Biosciences raises another massive round

In the Lab Alia Sajani and Angus Chen

CAR-T cell therapy’s complications, as well as its benefits, become clearer in ‘flurry’ of cancer studies

The Readout Elaine Chen

STAT Plus: Can you get satiety with GLP-1s without the nausea?

The Readout Elaine Chen

STAT Plus: uniQure shares soar on Huntington’s data

The Readout Elaine Chen

STAT Plus: Lilly’s obesity drug looks more potent than Novo’s in observational study